Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04986332
Other study ID # MACH Study
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2021
Est. completion date September 1, 2026

Study information

Verified date February 2023
Source Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Contact Domenico Di Raimondo
Phone +390916552180
Email domenico.diraimondo@unipa.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The MACH Study trial will examine the impact on high complexity COPD patients of a multidimensional approach (moderate-intensity physical activity program and clinic-therapeutic re-evaluation of the participants)


Description:

MACH Study investigators designed a trial to evaluate in high complexity subjects (at least 2 chronic diseases): - in the COPD cohort, the impact of a multidimensional approach involving global therapeutic remodeling (re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions) plus a 24-weeks moderate intensity physical activity program on: number of total and severe exacerbations; number of total and COPD/related hospitalizations; quality of life; survival over a 36 months follow-up period; - to establish whether a higher index of comorbidity and polypharmacy is independently associated with a worst clinical severity of COPD, an increased risk of exacerbations and a reduced survival; - the role played by specific clinical-laboratory markers of comorbidity (blood iron profile, hemochromocytometric parameters, renal function, blood pressure profile, glycemic compensation, Body Mass Index, lipid profile) and specific multidimensional tests in identifying COPD patients with higher clinical risk of rapid disease decline and/or higher risk of exacerbations and COPD-related hospitalizations; - to establish the role of Heart Failure as the most impactful comorbidity of COPD: assess the incidence rate and the relative risk of total/severe exacerbation and the incidence rate and the relative risk of total/COPD-related hospitalizations in Heart Failure/COPD patients over a 36-months follow-up period; - at the enrollment time (zero time) and after 12, 24 and 36 months, circulating levels of several systemic inflammation biomarkers. Correlate their variation over time with the comorbidity indexes, global pharmacological therapeutic redefinition and lifestyle intervention centered on 24-weeks physical activity program; - at the enrollment time (zero time) and after 12, 24 and 36 months, plasma levels of the main miRNAs involved in the COPD pathogenesis. Correlate their variation over time with the comorbidity indexes, global pharmacological therapeutic redefinition and lifestyle intervention centered on 24-weeks physical activity program; - at the enrollment time (zero time) and after 12, 24 and 36 months, plasma levels of the main myokines currently associated with the systemic effects of physical activity, correlating their baseline concentration to clinical-anthropometric parameters and type and number of chronic diseases and their variation over time in relation to the global pharmacological therapeutic redefinition and the 24-weeks physical activity program;


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date September 1, 2026
Est. primary completion date September 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria: - Provide signed and dated informed consent form; - Willing to comply with all study procedures and be available for the duration of the study; - COPD diagnosis (according to "Global Initiative for Chronic Obstructive Lung Disease" (GOLD) 2020 Guidelines) or HF diagnosis (according to European Society of Cardiology (ESC) 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure); - Diagnosis at least two other chronic diseases, in addition to COPD (Group A) or HF (Group B). If COPD and HF diagnoses are both present in the same subject, COPD or HF will be considered as the index pathology in view of the clinical relevance and ergo, the participant will be included in the group A or in the group B; - Healthy subjects exclusively for Group C; Chronic diseases are considered the following: - Type 1 or Type 2 Diabetes mellitus - Essential hypertension - Chronic Kidney Disease Stage 3b or worst (Glomerular Filtration Rate < 44 mL/min/1.73 m^2 estimated through the Cockcroft-Gault formule) - Chronic Anemia of moderate level of lower (Haemoglobin levels =10.9 g/dl) according to World Health Organization (WHO) classification - Chronic liver disease (every etiology) - Obesity (Body Mass Index = 30) Exclusion Criteria: - Active cigarette smoking; - Need for continuous supportive oxygen therapy, regardless of the flow required; - Distance covered during the 6 minutes walking test (6MWT) < 300 meters; - Unstable angina pectoris or angina pectoris at rest, a history of cardiac arrest, "New York Heart Association" (NYHA) Class III or IV congestive heart failure or severe left ventricular systolic dysfunction (EF <30%), acute myocarditis, pericarditis or hypertrophic myocardiopathy, clinically significant aortic stenosis, cardiac defibrillator, heart transplant, history of aortic aneurysm of at least 7 cm in diameter or aortic aneurysm repair; - Uncontrolled or partially controlled asthma despite optimal treatment; Sleep apnea syndrome; history of pulmonary fibrosis; - Recent acute cardiac or cerebral event in the last six months; - Child-Pugh B/C cirrhosis; - Body Mass Index = 35; - Evidence of any arrhythmia (uncontrolled atrial fibrillation (heart rate of 100 beats per minute or more), left bundle branch block or cardiac pacemaker, etc.) that contraindicates or makes unsafe the fulfilment of the regular physical activity program, assessed on the basis of the clinical history, documentation presented and clinical and instrumental evaluation carried out at the time of enrollment; - Resting heart rate less than 45 beats per minute or greater than 100 beats per minute; - History of uncontrolled or partially controlled high blood pressure despite optimal treatment; - Regular physical activity practice (the level of habitual physical activity practiced will be ascertained by administering specific questionnaires. Only sedentary participants will be eligible); - Inability to perform the 24-weeks physical activity program for any cause (muscle, joint, respiratory, neurological, vascular, diabetes complications); - Any acute or chronic disease, already known at the time of enrollment, capable of altering systemic inflammation biomarkers and cytokine profile (e.g. sepsis, infections, immune-rheumatological diseases, hematological diseases, etc.). - Any muscle condition, inflammatory or not, capable of altering muscular myokines' release (polymyositis, rheumatic polymyalgia, fibromyalgia); - Acute bleeding at the time of enrollment or any anemia that would have been required urgent transfusion within the past three months; - Solid or hematological neoplasia under active (at the time of enrollment) or recent (ended less than 6 months earlier) chemo-radiotherapy treatment at the time of enrollment; - Current diagnosis of schizophrenia, other psychotic disorders or bipolar disorder uncontrolled or partially controlled despite optimal treatment; - Self-report of alcohol or substance abuse within the past twelve months, current consumption of more than 14 alcoholic drinks per week, and/or current acute treatment or rehabilitation program for these problems; - Severe cognitive impairment or anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study; - Conditions not specifically mentioned above that may serve as criteria for exclusion at the discretion of the PI and study staff;

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Physical activity program
24-weeks moderate-intensity physical activity program
Other:
Global therapeutic remodeling
Re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions

Locations

Country Name City State
Italy Domenico Di Raimondo Palermo

Sponsors (1)

Lead Sponsor Collaborator
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative incidence of COPD exacerbation of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the number of COPD exacerbation per year.
The severity of COPD exacerbation will be assessed as follow:
Mild: treated with short acting bronchodilators only; Moderate: treated with bronchodilators and/or oral corticosteroids; Severe: patient requires hospitalization or visits the emergency room;
Baseline to 12 months
Primary Cumulative incidence of COPD exacerbation of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the number of COPD exacerbation per year.
The severity of COPD exacerbation will be assessed as follow:
Mild: treated with short acting bronchodilators only; Moderate: treated with bronchodilators and/or oral corticosteroids; Severe: patient requires hospitalization or visits the emergency room;
Baseline to 24 months
Primary Cumulative incidence of COPD exacerbation of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the number of COPD exacerbation per year.
The severity of COPD exacerbation will be assessed as follow:
Mild: treated with short acting bronchodilators only; Moderate: treated with bronchodilators and/or oral corticosteroids; Severe: patient requires hospitalization or visits the emergency room;
Baseline to 36 months
Primary Cumulative incidence of hospitalization for pneumonia of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the number of hospitalization per year for pneumonia.
Pneumonia will be ascertain clinically and/or radiologically.
Baseline to 12 months
Primary Cumulative incidence of hospitalization for pneumonia of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the number of hospitalization per year for pneumonia.
Pneumonia will be ascertain clinically and/or radiologically.
Baseline to 24 months
Primary Cumulative incidence of hospitalization for pneumonia of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the number of hospitalization per year for severe COPD exacerbation and pneumonia.
Pneumonia will be ascertain clinically and/or radiologically.
Baseline to 36 months
Primary Cumulative incidence of hospitalizations for any cause of Group A The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the number of hospitalization for any cause per year. Baseline to 12 months
Primary Cumulative incidence of hospitalizations for any cause of Group A The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the number of hospitalization for any cause per year. Baseline to 24 months
Primary Cumulative incidence of hospitalizations for any cause of Group A The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the number of hospitalization for any cause per year. Baseline to 36 months
Primary Mortality rate of Group "COPD" The number of total deaths in the time frame of 12 months in Group "COPD" Baseline to 12 months
Primary Mortality rate of Group "COPD" The number of total deaths in the time frame of 24 months in Group "COPD" Baseline to 24 months
Primary Mortality rate of Group "COPD" The number of total deaths in the time frame of 36 months in Group "COPD" Baseline to 36 months
Primary Change over time from baseline in Mini Nutritional Assessment-Short Form total score of Group "COPD" Mini Nutritional Assessment is a simple tool that helps physicians to have knowledge of nutritional status in elderly persons. It was well validated in the hospital, community and long-term care settings. Baseline to post-interventions at 12 months
Primary Change over time from baseline in Mini Nutritional Assessment-Short Form total score of Group "COPD" Mini Nutritional Assessment is a simple tool that helps physicians to have knowledge of nutritional status in elderly persons. It was well validated in the hospital, community and long-term care settings. Baseline to 24 months
Primary Change over time from baseline in Mini Nutritional Assessment-Short Form total score of Group "COPD" Mini Nutritional Assessment is a simple tool that helps physicians to have knowledge of nutritional status in elderly persons. It was well validated in the hospital, community and long-term care settings. Baseline to 36 months
Primary Change over time from baseline in EQ-5D-3L of Group "COPD" The EQ-5D-3L is a generic, multidimensional, health-related, quality-of-life instrument using a three-level scale 1-3 (no problem, some problems and extreme problems) Baseline to post-interventions at 12 months
Primary Change over time from baseline in EQ-5D-3L of Group "COPD" The EQ-5D-3L is a generic, multidimensional, health-related, quality-of-life instrument using a three-level scale 1-3 (no problem, some problems and extreme problems) Baseline to 24 months
Primary Change over time from baseline in EQ-5D-3L of Group "COPD" The EQ-5D-3L is a generic, multidimensional, health-related, quality-of-life instrument using a three-level scale 1-3 (no problem, some problems and extreme problems) Baseline to 36 months
Primary Change over time from baseline in mMRC of Group "COPD" mMRC is a simple tool that investigates the measure of breathlessness of COPD subjects.
Grade 0: "I only get breathless with strenuous exercise " Grade 1: I get short of breath when hurrying on the level or walking up a slight hill" Grade 2: "I walk slower than people of same age on the level because of breathlessness or I have to stop to catch breath when walking at their own pace on the level" Grade 3: "I stop for breath after walking ~100 m or after few minutes on the level" Grade 4: "I am too breathless to leave the house, or breathless when dressing or undressing"
Baseline to post-interventions at 12 months
Primary Change over time from baseline in mMRC of Group "COPD" mMRC is a simple tool that investigates the measure of breathlessness of COPD subjects.
Grade 0: "I only get breathless with strenuous exercise " Grade 1: I get short of breath when hurrying on the level or walking up a slight hill" Grade 2: "I walk slower than people of same age on the level because of breathlessness or I have to stop to catch breath when walking at their own pace on the level" Grade 3: "I stop for breath after walking ~100 m or after few minutes on the level" Grade 4: "I am too breathless to leave the house, or breathless when dressing or undressing"
Baseline to 24 months
Primary Change over time from baseline in mMRC of Group "COPD" mMRC is a simple tool that investigates the measure of breathlessness of COPD subjects.
Grade 0: "I only get breathless with strenuous exercise " Grade 1: I get short of breath when hurrying on the level or walking up a slight hill" Grade 2: "I walk slower than people of same age on the level because of breathlessness or I have to stop to catch breath when walking at their own pace on the level" Grade 3: "I stop for breath after walking ~100 m or after few minutes on the level" Grade 4: "I am too breathless to leave the house, or breathless when dressing or undressing"
Baseline to 36 months
Primary Change over time from baseline in CAT of Group "COPD" The COPD Assessment Test (CAT) is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time. The CAT is simple to administer, and aims to help clinicians, with their patients, better manage COPD. Baseline to post-interventions at 12 months
Primary Change over time from baseline in CAT of Group "COPD" The COPD Assessment Test (CAT) is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time. The CAT is simple to administer, and aims to help clinicians, with their patients, better manage COPD. Baseline to 24 months
Primary Change over time from baseline in CAT of Group "COPD" The COPD Assessment Test (CAT) is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time. The CAT is simple to administer, and aims to help clinicians, with their patients, better manage COPD. Baseline to 36 months
Primary Change over time from baseline in Barthel Index of Group "COPD" The Maryland Disability Index (formally Barthel Index) was codified in the late 1950s by the english nurse Barthel. It allows to have knowledge of the degree of subject's independence. It consists of 10 items that explore common "Activities of Daily Living (ADL)", from nutrition to the ability to climb or descend stairs. Each item is assigned an arbitrary score of 5, 10 or 15 points (maximum 100). The sum indicates the degree of autonomy of the patient in carrying out daily activities. Baseline to post interventions at 12 months
Primary Change over time from baseline in Barthel Index of Group "COPD" The Maryland Disability Index (formally Barthel Index) was codified in the late 1950s by the english nurse Barthel. It allows to have knowledge of the degree of subject's independence. It consists of 10 items that explore common "Activities of Daily Living (ADL)", from nutrition to the ability to climb or descend stairs. Each item is assigned an arbitrary score of 5, 10 or 15 points (maximum 100). The sum indicates the degree of autonomy of the patient in carrying out daily activities. Baseline to 24 months
Primary Change over time from baseline in Barthel Index of Group "COPD" The Maryland Disability Index (formally Barthel Index) was codified in the late 1950s by the english nurse Barthel. It allows to have knowledge of the degree of subject's independence. It consists of 10 items that explore common "Activities of Daily Living (ADL)", from nutrition to the ability to climb or descend stairs. Each item is assigned an arbitrary score of 5, 10 or 15 points (maximum 100). The sum indicates the degree of autonomy of the patient in carrying out daily activities. Baseline to 36 months
Primary Change over time from baseline in 6-minutes Walking Test (6-mWT) of Group "COPD" The 6-mWT measures the distance a subject walks while walking fast. The protocol used is standardized (a protocol with written instructions identical for all is used) and performed by specially trained personnel Baseline to post interventions at 12 months
Primary Change over time from baseline in 6-minutes Walking Test (6-mWT) of Group "COPD" The 6-mWT measures the distance a subject walks while walking fast. The protocol used is standardized (a protocol with written instructions identical for all is used) and performed by specially trained personnel Baseline to 24 months
Primary Change over time from baseline in 6-minutes Walking Test (6-mWT) of Group "COPD" The 6-mWT measures the distance a subject walks while walking fast. The protocol used is standardized (a protocol with written instructions identical for all is used) and performed by specially trained personnel Baseline to 36 months
Primary Change over time from baseline in BODE Index of Group "COPD" The BODE index, for Body-mass index, airflow Obstruction, Dyspnea, and Exercise, is a multidimensional scoring system and capacity index originally designed to predict mortality in patients with COPD. Baseline to post-interventions at 12 months
Primary Change over time from baseline in BODE Index of Group "COPD" The BODE index, for Body-mass index, airflow Obstruction, Dyspnea, and Exercise, is a multidimensional scoring system and capacity index originally designed to predict mortality in patients with COPD. Baseline to 24 months
Primary Change over time from baseline in BODE Index of Group "COPD" The BODE index, for Body-mass index, airflow Obstruction, Dyspnea, and Exercise, is a multidimensional scoring system and capacity index originally designed to predict mortality in patients with COPD. Baseline to 36 months
Primary Change over time from baseline in 24-hour average systolic and diastolic pressures of Group "COPD" 24-hour average systolic and diastolic pressures will be assessed performing a 24-hour Ambulatory Blood Pressure Monitoring. Baseline to post-interventions at 12 months
Primary Change over time from baseline in 24-hour average systolic and diastolic pressures of Group "COPD" 24-hour average systolic and diastolic pressures will be assessed performing a 24-hour Ambulatory Blood Pressure Monitoring. Baseline to 24 months
Primary Change over time from baseline in 24-hour average systolic and diastolic pressures of Group "COPD" 24-hour average systolic and diastolic pressures will be assessed performing a 24-hour Ambulatory Blood Pressure Monitoring. Baseline to 36 months
Primary Change over time from baseline in heart rate variability of Group "COPD" Heart rate variability will be assessed performing a 24-ECG Holter Baseline to post-interventions at 12 months
Primary Change over time from baseline in heart rate variability of Group "COPD" Heart rate variability will be assessed performing a 24-ECG Holter Baseline to 24 months
Primary Change over time from baseline in heart rate variability of Group "COPD" Heart rate variability will be assessed performing a 24-ECG Holter Baseline to 36 months
Primary Change over time from baseline in fasting blood sugar of Group "COPD" Fasting blood sugar will be performed using the the dextrostix Baseline to post-interventions at 12 months
Primary Change over time from baseline in fasting blood sugar of Group "COPD" Fasting blood sugar will be performed using the the dextrostix Baseline to 24 months
Primary Change over time from baseline in fasting blood sugar of Group "COPD" Fasting blood sugar will be performed using the the dextrostix Baseline to 36 months
Primary Variation over time (percentage/year) of Forced Expiratory Volume in the 1st second (FEV1) of Group "COPD" Forced Expiratory Volume in the 1st second (FEV1) will be assessed performing the spirometric test Baseline to post-interventions at 12 months
Primary Variation over time (percentage/year) of Forced Expiratory Volume in the 1st second (FEV1) of Group "COPD" Forced Expiratory Volume in the 1st second (FEV1) will be assessed performing the spirometric test Baseline to 24 months
Primary Variation over time (percentage/year) of Forced Expiratory Volume in the 1st second (FEV1) of Group "COPD" Forced Expiratory Volume in the 1st second (FEV1) will be assessed performing the spirometric test Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of Interleukin-6 (IL-6) (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-6 (pg/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of Interleukin-6 (IL-6) (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-6 (pg/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of Interleukin-6 (IL-6) (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-6 (pg/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of IL-8 (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-8 (pg/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of IL-8 (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-8 (pg/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of IL-8 (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-8 (pg/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of IL-10 (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-10 (pg/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of IL-10 (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-10 (pg/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of IL-10 (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-10 (pg/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of IL-15 (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-15 (pg/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of IL-15 (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-15 (pg/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of IL-15 (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-15 (pg/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of Tumor Necrosis Factor- a (TNF-a) (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Tumor Necrosis Factor- a (TNF-a) (pg/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of Tumor Necrosis Factor- a (TNF-a) (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Tumor Necrosis Factor- a (TNF-a) (pg/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of Tumor Necrosis Factor- a (TNF-a) (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Tumor Necrosis Factor- a (TNF-a) (pg/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of IL-1ß (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-1ß (pg/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of IL-1ß (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-1ß (pg/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of IL-1ß (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-1ß (pg/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of IL-1ra (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-1ra (pg/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of IL-1ra (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-1ra (pg/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of IL-1ra (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of IL-1ra (pg/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of soluble Tumor Necrosis Factor receptors (sTNFr) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of soluble Tumor Necrosis Factor receptors (sTNFr) (ng/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of soluble Tumor Necrosis Factor receptors (sTNFr) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of soluble Tumor Necrosis Factor receptors (sTNFr) (ng/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of soluble Tumor Necrosis Factor receptors (sTNFr) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of soluble Tumor Necrosis Factor receptors (sTNFr) (ng/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of Vascular Endothelial Growth Factor (VEGF) (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Vascular Endothelial Growth Factor (VEGF) (pg/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of Vascular Endothelial Growth Factor (VEGF) (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Vascular Endothelial Growth Factor (VEGF) (pg/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of Vascular Endothelial Growth Factor (VEGF) (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Vascular Endothelial Growth Factor (VEGF) (pg/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of Brain Derived Neurotrophic Factor (BDNF) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Brain Derived Neurotrophic Factor (BDNF) (ng/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of Brain Derived Neurotrophic Factor (BDNF) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Brain Derived Neurotrophic Factor (BDNF) (ng/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of Brain Derived Neurotrophic Factor (BDNF) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Brain Derived Neurotrophic Factor (BDNF) (ng/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of Insulin-like growth factor 1 (IGF-1) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Insulin-like growth factor 1 (IGF-1) (ng/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of Insulin-like growth factor 1 (IGF-1) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Insulin-like growth factor 1 (IGF-1) (ng/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of Insulin-like growth factor 1 (IGF-1) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Insulin-like growth factor 1 (IGF-1) (ng/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of Transforming Growth Factor-ß (TGF-ß) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Transforming Growth Factor-ß (TGF-ß) (ng/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of Transforming Growth Factor-ß (TGF-ß) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Transforming Growth Factor-ß (TGF-ß) (ng/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of Transforming Growth Factor-ß (TGF-ß) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Transforming Growth Factor-ß (TGF-ß) (ng/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of Irisin (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Irisin (ng/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of Irisin (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Irisin (ng/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of Irisin (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Irisin (ng/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of Myostatin (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Myostatin (pg/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of Myostatin (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Myostatin (pg/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of Myostatin (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Myostatin (pg/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of Follistatin (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Follistatin (pg/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of Follistatin (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Follistatin (pg/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of Follistatin (pg/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of Follistatin (pg/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline on the circulating levels of ß-aminoisobutyric acid (BAIBA) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of ß-aminoisobutyric acid (BAIBA) (ng/mL) of Group "COPD" Baseline to post-interventions at 12 months
Secondary Change over time from baseline on the circulating levels of ß-aminoisobutyric acid (BAIBA) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of ß-aminoisobutyric acid (BAIBA) (ng/mL) of Group "COPD" Baseline to 24 months
Secondary Change over time from baseline on the circulating levels of ß-aminoisobutyric acid (BAIBA) (ng/mL) of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions on the circulating levels of ß-aminoisobutyric acid (BAIBA) (ng/mL) of Group "COPD" Baseline to 36 months
Secondary Change over time from baseline in miRNAs serum expression of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions in miRNAs serum expression of Group "COPD"
miRNA-1,
miRNA-21,
miRNA-210,
miRNA-221,
miRNA-223,
miRNA-1274a,
miRNA-101,
miRNA-144,
miRNA-133a,
miRNA-133b,
miRNA-206,
miRNA-208a,
miRNA-208b,
miRNA-499,
miRNA-532
miRNA-181a
Baseline to post-interventions at 12 months
Secondary Change over time from baseline in miRNAs serum expression of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions in miRNAs serum expression of Group "COPD"
miRNA-1,
miRNA-21,
miRNA-210,
miRNA-221,
miRNA-223,
miRNA-1274a,
miRNA-101,
miRNA-144,
miRNA-133a,
miRNA-133b,
miRNA-206,
miRNA-208a,
miRNA-208b,
miRNA-499,
miRNA-532
miRNA-181a
Baseline to 24 months
Secondary Change over time from baseline in miRNAs serum expression of Group "COPD" The effect of a 24-weeks moderate-intensity physical activity program and re-assessing and therapeutic optimization of the whole burden of chronic pathologic conditions in miRNAs serum expression of Group "COPD"
miRNA-1,
miRNA-21,
miRNA-210,
miRNA-221,
miRNA-223,
miRNA-1274a,
miRNA-101,
miRNA-144,
miRNA-133a,
miRNA-133b,
miRNA-206,
miRNA-208a,
miRNA-208b,
miRNA-499,
miRNA-532
miRNA-181a
Baseline to 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy